Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 4/20 | 0.43 |
| ▸ | NOS1 | P29475 | 4/20 | 0.43 |
| ▸ | NOS2 | P35228 | 4/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.35 |
| ▸ | RIOK2 | Q9BVS4 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29693665 | 1.00 | CCR1 (0.46) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL30225309 | 0.82 | ATP1A1 (0.33) | NPC1CYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL30225298 | 0.81 | HTT (0.37) | MAPTCYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL2377916 | 0.80 | PARP15 (0.36) | CYP2C9 | |
| SCHEMBL2380155 | 0.79 | CFTR (0.38) | — | |
| SCHEMBL29851063 | 0.78 | KDM4E (0.43) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL1671463 | 0.78 | KDM4E (0.43) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL23124290 | 0.77 | TLR8 (0.36) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL29929888 | 0.77 | ALDH1A1 (0.37) | CCR1NOS1NOS2MAPTNPC1 | |
| SCHEMBL16584984 | 0.77 | TLR8 (0.32) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12559502-B2 | Thieno pyrimidines as ferroportin inhibitors | Global Blood Therapeutics, Inc (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| WO-2025038863-A1 | INDOLE AND PYRROLOYPYRIDINE DERIVATIVES AS GPR17 MODULATORS | BIOGEN MA INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2024-09-10 | — | — | US | disclosed |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-2550273-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| US-20110319426-A1 | Substituted Isoindoles | ASTRAZENECA AB (SE) | 2011-12-29 | — | — | US | disclosed |
| US-8030500-B2 | Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies | ASTRAZENECA AB (SE) | 2011-10-04 | — | — | US | disclosed |
| WO-2011117145-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| EP-2367814-A1 | NEW COMPOUNDS 578 | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
| US-20100125082-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056194-A1 | 5H-PYRROLO [ 3, 4-B] PYRIDIN DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125081-A1 | NEW COMPOUNDS 574 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056196-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | CCR1 3148/4885CCR5 1892/4885CCR8 4345/4885 |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | CCR1 940/4885CCR5 496/4885CCR8 1412/4885 |
| US-20100125082-A1 | NEW COMPOUNDS 578 | PSEN1, PSEN2, BACE1 | CCR1 3931/4885CCR5 1200/4885CCR8 2580/4885 |
| US-12559502-B2 | Thieno pyrimidines as ferroportin inhibitors | HAMP, TFRC, SLC40A1 | CCR1 74/4885CCR5 140/4885CCR8 542/4885 |
| US-20100125081-A1 | NEW COMPOUNDS 574 | PSEN1, PSEN2, BACE1 | CCR1 4133/4885CCR5 1210/4885CCR8 4655/4885 |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | CCR1 2972/4885CCR5 1022/4885CCR8 2105/4885 |
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | CCR1 1085/4885CCR5 669/4885CCR8 2284/4885 |
| US-20110319426-A1 | Substituted Isoindoles | PSEN2, PSEN1, SNCA | CCR1 4371/4885CCR5 1219/4885CCR8 4690/4885 |
| US-11814376-B2 | Hepatitis b core protein modulators | HAVCR2, FABP1, MAVS | CCR1 2972/4885CCR5 1022/4885CCR8 2105/4885 |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | CCR1 940/4885CCR5 496/4885CCR8 1412/4885 |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | CCR1 940/4885CCR5 496/4885CCR8 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.